A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
Epistemonikos ID: ca22e55a2270e8cda85efb7cc01e5b25439f85dc
First added on: Mar 23, 2020